GLP-1 SM

GLP-1 SM is a synthetic peptide composed of 31 amino acids that shares 94% structural similarity with native human GLP-1 (glucagon-like peptide-1). GLP-1 SM is one of the most extensively studied incretin-based therapies in modern medicine.

The peptide features two amino acid substitutions and a C-18 fatty acid side chain that extends its half-life to approximately 7 days, compared to just 1.5 minutes for native GLP-1. This allows for once-weekly administration in clinical settings.

Semaglutide has been approved by the FDA under multiple brand names for type 2 diabetes and chronic weight management. It works by activating the GLP-1 receptor, which stimulates insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite.

Research-grade GLP-1 SM sold as a lyophilized peptide is not equivalent to FDA-approved formulations and is sold strictly for laboratory and research purposes only.